Clinical Trials
294 trialsNCT00906893 2026-05-14
MISOGLIO
University Hospital, Bordeaux
Phase 2 Completed
NCT03797326 2026-05-04
LEAP-005
Merck Sharp & Dohme LLC
Phase 2 Completed
NCT04817254 2026-04-17
Association of Peripheral Blood Immunologic Response to Therapeutic Response to Adjuvant Treatment With Immune Checkpoint Inhibition (ICI) in Patients With Newly Diagnosed Glioblastoma or Gliosarcoma
National Institutes of Health Clinical Center (CC)
Phase 2 Completed
NCT03475186 2026-03-13
Testing Ramipril to Prevent Memory Loss in People With Glioblastoma
Wake Forest University Health Sciences
Phase 2 Completed
NCT04044937 2026-03-11
UC-GlioFET
University of California, San Francisco
Phase 2 Completed
NCT02617745 2026-01-02
GLIOPLAK
Centre Henri Becquerel
Phase 2 Completed
NCT04391062 2025-12-05
DOSINDYGO
University Hospital, Lille
Phase 2 Completed
NCT01582269 2025-11-24
A Study in Recurrent Glioblastoma (GB)
Eli Lilly and Company
Phase 2 Completed
NCT03532295 2025-11-21
Retifanlimab and Epacadostat in Combination With Radiation and Bevacizumab in Patients With Recurrent Gliomas
Washington University School of Medicine
Phase 2 Completed
NCT03746080 2025-11-14
Whole Brain Radiation Therapy With Standard Temozolomide Chemo-Radiotherapy and Plerixafor in Treating Patients With Glioblastoma
Stanford University
Phase 2 Completed
NCT06439420 2025-10-01
CBT-I in PBT
Virginia Commonwealth University
Phase 2 Completed
NCT05608395 2025-09-25
GlioMET
Masaryk Memorial Cancer Institute
Phase 2 Completed
NCT03050736 2025-09-04
Safety Study of VAL-083 and Radiotherapy in Patients With Newly Diagnosed GBM Having Unmethylated MGMT Expression
Kintara Therapeutics, Inc.
Phase 2 Completed
NCT02717962 2025-08-29
Study of VAL-083 in Patients With MGMT Unmethylated, Bevacizumab-naive Glioblastoma in the Adjuvant or Recurrent Setting
Kintara Therapeutics, Inc.
Phase 2 Completed
NCT01931098 2025-08-11
Oral Pazopanib Plus Oral Topotecan Metronomic Antiangiogenic Therapy for Recurrent Glioblastoma Multiforme (A) Without Prior Bevacizumab Exposure and (B) After Failing Prior Bevacizumab
National Institutes of Health Clinical Center (CC)
Phase 2 Completed
NCT03137888 2025-08-03
Spectroscopic MRI-Guided Radiation Therapy Planning in Glioblastoma
Emory University
Phase 2 Completed
NCT02986178 2025-07-11
Lerapolturev in Recurrent Malignant Glioma
Istari Oncology, Inc.
Phase 2 Completed
NCT03778294 2025-07-03
18F-DOPA-PET/MRI Scan in Imaging Elderly Patients With Newly Diagnosed Grade IV Malignant Glioma or Glioblastoma During Planning for a Short Course of Proton Beam Radiation Therapy
Mayo Clinic
Phase 2 Completed
NCT02781792 2025-06-27
Temozolomide Chronotherapy for High Grade Glioma
Washington University School of Medicine
Phase 2 Completed
NCT04743310 2025-06-13
Fluorescence Detection of Adult Primary Central Nervous System Tumors With Tozuleristide and the Canvas System
Cedars-Sinai Medical Center
Phase 2 Completed
NCT04740190 2025-06-11
TAC-GReD
The University of Hong Kong
Phase 2 Completed
NCT04051606 2025-06-05
Regorafenib in Bevacizumab Refractory Recurrent Glioblastoma
Case Comprehensive Cancer Center
Phase 2 Completed
NCT04479241 2025-06-05
LUMINOS-101: Lerapolturev (PVSRIPO) and Pembrolizumab in Patients With Recurrent Glioblastoma
Istari Oncology, Inc.
Phase 2 Completed
NCT04704154 2025-04-18
A Trial to Learn Whether Regorafenib in Combination With Nivolumab Can Improve Tumor Responses and How Safe it is for Participants With Solid Tumors
Bayer
Phase 2 Completed
NCT03522298 2025-03-24
Safety, Pharmacokinetics and Efficacy of Paxalisib (GDC-0084) in Newly-diagnosed Glioblastoma
Kazia Therapeutics Limited
Phase 2 Completed
NCT01894061 2025-02-17
NovoTTF-100A With Bevacizumab (Avastin) in Patients With Recurrent Glioblastoma
Case Comprehensive Cancer Center
Phase 2 Completed
NCT02465268 2025-01-14
ATTAC-II
University of Florida
Phase 2 Completed
NCT04280848 2025-01-09
UCPVax-Glio
Centre Hospitalier Universitaire de Besancon
Phase 2 Completed
NCT01464177 2024-12-09
GBM Hypo RT
University of Sao Paulo
Phase 2 Completed
NCT03732352 2024-11-12
18F-FDG PET and Osimertinib in Evaluating Glucose Utilization in Patients with EGFR Activated Recurrent Glioblastoma
Jonsson Comprehensive Cancer Center
Phase 2 Completed
NCT04845919 2024-11-12
Sonic ALA
Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta
Phase 2 Completed
NCT01149850 2024-09-19
Bevacizumab and Temozolomide in Treating Older Patients With Newly-Diagnosed Glioblastoma Multiforme or Gliosarcoma
Jonsson Comprehensive Cancer Center
Phase 2 Completed
NCT03661723 2024-09-19
Pembrolizumab and Reirradiation in Bevacizumab Naïve and Bevacizumab Resistant Recurrent Glioblastoma
Dana-Farber Cancer Institute
Phase 2 Completed
NCT01204684 2024-08-28
Dendritic Cell Vaccine for Patients With Brain Tumors
Jonsson Comprehensive Cancer Center
Phase 2 Completed
NCT04013672 2024-08-28
Study of Pembrolizumab Plus SurVaxM for Glioblastoma at First Recurrence
Case Comprehensive Cancer Center
Phase 2 Completed
NCT04492163 2024-08-16
Open-Label Pilot Study of OPTUNE® With High Density Transducer Arrays for the Treatment of Recurrent GBM
NovoCure Ltd.
Phase 2 Completed
NCT01817751 2024-07-17
Sorafenib, Valproic Acid, and Sildenafil in Treating Patients With Recurrent High-Grade Glioma
Virginia Commonwealth University
Phase 2 Completed
NCT02014844 2024-05-29
Phase 2 Study to Investigate the Efficacy and Safety of Aldoxorubicin in Subjects With Glioblastoma
ImmunityBio, Inc.
Phase 2 Completed
NCT02067156 2024-05-21
Efficacy, Safety and CNS Exposure of G-202 (Mipsagargin) in Patients With Recurrent or Progressive Glioblastoma
GenSpera, Inc.
Phase 2 Completed
NCT03139916 2024-05-16
Bavituximab With Radiation and Temozolomide for Patients With Newly Diagnosed Glioblastoma
Massachusetts General Hospital
Phase 2 Completed
NCT00445965 2024-04-04
Iodine I 131 Monoclonal Antibody 3F8 in Treating Patients With Central Nervous System Cancer or Leptomeningeal Cancer
Memorial Sloan Kettering Cancer Center
Phase 2 Completed
NCT00589875 2024-04-03
BrTK02
Candel Therapeutics, Inc.
Phase 2 Completed
NCT00704288 2024-02-05
Study of XL184 (Cabozantinib) in Adults With Glioblastoma Multiforme
Exelixis
Phase 2 Completed
NCT02206230 2024-01-31
Trial of Hypofractionated Radiation Therapy for Glioblastoma
AHS Cancer Control Alberta
Phase 2 Completed
NCT01854554 2024-01-02
Glioblastoma Multiforme (GBM) Proton vs. Intensity Modulated Radiotherapy (IMRT)
M.D. Anderson Cancer Center
Phase 2 Completed
NCT02684058 2023-12-13
Study of Efficacy and Safety of Dabrafenib in Combination With Trametinib in Pediatric Patients With BRAF V600 Mutation Positive LGG or Relapsed or Refractory HGG Tumors
Novartis
Phase 2 Completed
NCT03027388 2023-11-22
Protein Phosphatase 2A Inhibitor, in Recurrent Glioblastoma
National Institutes of Health Clinical Center (CC)
Phase 2 Completed
NCT01259869 2023-08-22
A Study of PX-866 in Patients With Glioblastoma Multiforme at Time of First Relapse or Progression
Canadian Cancer Trials Group
Phase 2 Completed
NCT02330991 2023-07-24
A Trial of One-week on/One-week Off Temozolomide Versus Continuous Dose-Intense Temozolomide in Patients With Glioblastoma Multiforme at First Relapse
Beijing Sanbo Brain Hospital
Phase 2 Completed
NCT01290692 2023-07-03
Study To Test the Safety and Efficacy of TVI-Brain-1 As A Treatment for Recurrent Grade IV Glioma
TVAX Biomedical
Phase 2 Completed